Literature DB >> 33241425

Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population.

Shany Sherman1, Noa Kremer, Adam Dalal, Efrat Solomon-Cohen, Einav Berkovich, Yehonatan Noyman, Maya Ben-Lassan, Assi Levi, Lev Pavlovsky, Hadas Prag Naveh, Emmilia Hodak, Iris Amitay-Laish.   

Abstract

Patients with mycosis fungoides (MF) are thought to be at increased risk of melanoma. However, studies addressing surveillance-bias and treatments as a possible confounder are lacking. This retrospective study compared the prevalence and risk of melanoma between 982 patients with MF, and 3,165 patients with psoriasis attending tertiary cutaneous-lymphoma/psoriasis clinics during 2009 to 2018. Melanoma was diagnosed in 47 patients with MF (4.8%; 43 early-stage) and in 23 patients with psoriasis (0.7%) (odds ratio 6.6, p < 0.0001). In 60% of patients, MF/psoriasis preceded melanoma diagnosis. Hazard ratio (HR) for a subsequent melanoma in MF vs psoriasis was 6.3 (95% confidence interval (95% CI) 3.4-11.7, p < 0.0001). Compared with the general population, melanoma standardized incidence ratios were 17.5 in patients with MF (95% CI 11.0-23.9, p < 0.0001), and 2.2 (95% CI 0.6-3.8, p = 0.148) in patients with psoriasis. Narrow-band ultraviolet B was not a contributory factor (HR 1.15, 95% CI 0.62-2.14, p = 0.66). These findings add evidence that patients with MF have a significantly higher risk of melanoma, not only compared with the general population, but also compared with patients with psoriasis. This comorbidity may be inherent to MF.

Entities:  

Keywords:  hazard ratio; melanoma; phototherapy; psoriasis; standardized incidence ratio; mycosis fungoides

Mesh:

Year:  2020        PMID: 33241425      PMCID: PMC9309703          DOI: 10.2340/00015555-3704

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  38 in total

1.  Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.

Authors:  Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

Review 2.  The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Authors:  Rein Willemze; Lorenzo Cerroni; Werner Kempf; Emilio Berti; Fabio Facchetti; Steven H Swerdlow; Elaine S Jaffe
Journal:  Blood       Date:  2019-01-11       Impact factor: 22.113

3.  Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma.

Authors:  L Väkevä; E Pukkala; A Ranki
Journal:  J Invest Dermatol       Date:  2000-07       Impact factor: 8.551

Review 4.  Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.

Authors:  Shamir Geller; Haoming Xu; Mark Lebwohl; Beatrice Nardone; Mario E Lacouture; Meenal Kheterpal
Journal:  Am J Clin Dermatol       Date:  2018-06       Impact factor: 7.403

5.  Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

Authors:  Laura Y McGirt; Peilin Jia; Devin A Baerenwald; Robert J Duszynski; Kimberly B Dahlman; John A Zic; Jeffrey P Zwerner; Donald Hucks; Utpal Dave; Zhongming Zhao; Christine M Eischen
Journal:  Blood       Date:  2015-06-16       Impact factor: 22.113

6.  Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis.

Authors:  Amrita Goyal; Daniel O'Leary; Kavita Goyal; Nathan Rubin; Kimberly Bohjanen; Maria Hordinsky; Steven T Chen; Georgios Pongas; Lyn M Duncan; Aleksandr Lazaryan
Journal:  J Am Acad Dermatol       Date:  2019-07-30       Impact factor: 11.527

Review 7.  Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.

Authors:  A G Licata; L D Wilson; I M Braverman; A M Feldman; B M Kacinski
Journal:  Arch Dermatol       Date:  1995-04

8.  Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin.

Authors:  Olivier Dereure; Edi Levi; Eric C Vonderheid; Marshall E Kadin
Journal:  J Invest Dermatol       Date:  2002-06       Impact factor: 8.551

9.  Introduction to the Analysis of Survival Data in the Presence of Competing Risks.

Authors:  Peter C Austin; Douglas S Lee; Jason P Fine
Journal:  Circulation       Date:  2016-02-09       Impact factor: 29.690

10.  Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma.

Authors:  Gil Bar-Sela; Reuven Bergman
Journal:  JAAD Case Rep       Date:  2015-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.